<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This session addressed <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> (APL), <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In particular, <z:chebi fb="0" ids="30621">arsenic trioxide</z:chebi> as a treatment for APL, one of the most highly curable types of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, was discussed </plain></SENT>
<SENT sid="2" pm="."><plain>Speakers also discussed the use of combination regimens in clinical trials for <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> treatments and therapeutic agents in the treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
</text></document>